These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 30315639

  • 21. EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells.
    Miura S, Kobune M, Horiguchi H, Kikuchi S, Iyama S, Murase K, Goto A, Ikeda H, Takada K, Miyanishi K, Kato J.
    Blood Cells Mol Dis; 2019 Sep; 78():1-8. PubMed ID: 31082798
    [Abstract] [Full Text] [Related]

  • 22. Erythropoietin administration increases splenic erythroferrone protein content and liver TMPRSS6 protein content in rats.
    Gurieva I, Frýdlová J, Rychtarčíková Z, Vokurka M, Truksa J, Krijt J.
    Blood Cells Mol Dis; 2017 May; 64():1-7. PubMed ID: 28282554
    [Abstract] [Full Text] [Related]

  • 23. Erythroferrone inhibits the induction of hepcidin by BMP6.
    Arezes J, Foy N, McHugh K, Sawant A, Quinkert D, Terraube V, Brinth A, Tam M, LaVallie ER, Taylor S, Armitage AE, Pasricha SR, Cunningham O, Lambert M, Draper SJ, Jasuja R, Drakesmith H.
    Blood; 2018 Oct 04; 132(14):1473-1477. PubMed ID: 30097509
    [Abstract] [Full Text] [Related]

  • 24. Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.
    Coffey R, Jung G, Olivera JD, Karin G, Pereira RC, Nemeth E, Ganz T.
    Blood; 2022 Jan 20; 139(3):439-451. PubMed ID: 34614145
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry.
    Castro-Mollo M, Gera S, Ruiz-Martinez M, Feola M, Gumerova A, Planoutene M, Clementelli C, Sangkhae V, Casu C, Kim SM, Ostland V, Han H, Nemeth E, Fleming R, Rivella S, Lizneva D, Yuen T, Zaidi M, Ginzburg Y.
    Elife; 2021 May 18; 10():. PubMed ID: 34002695
    [Abstract] [Full Text] [Related]

  • 28. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
    Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, Allen MR, White KE.
    Physiol Rep; 2020 Jun 18; 8(11):e14434. PubMed ID: 32476270
    [Abstract] [Full Text] [Related]

  • 29. Chronic intermittent hypobaric hypoxia improves iron metabolism disorders via the IL-6/JAK2/STAT3 and Epo/STAT5/ERFE signaling pathways in metabolic syndrome rats.
    Cui F, Sun J, Mi H, Li B, Tang L, Wang R, Du Y, Guo B, Li Y, Shi M.
    J Trace Elem Med Biol; 2023 Sep 18; 79():127259. PubMed ID: 37413927
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
    Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, Yamamoto T, Tomosugi N, Shibata T.
    PLoS One; 2016 Sep 18; 11(3):e0151601. PubMed ID: 26978524
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial.
    Breenfeldt Andersen A, Bonne TC, Bejder J, Jung G, Ganz T, Nemeth E, Olsen NV, Huertas JR, Nordsborg NB.
    Am J Physiol Regul Integr Comp Physiol; 2021 Aug 01; 321(2):R152-R161. PubMed ID: 34160288
    [Abstract] [Full Text] [Related]

  • 34. Erythropoiesis and Iron Parameters in Transfusion-dependent and Nontransfusion-dependent Thalassemias.
    Ozturk Z, Gumuslu S, Yalcin K, Kupesiz A.
    J Pediatr Hematol Oncol; 2021 Jul 01; 43(5):186-192. PubMed ID: 34157011
    [Abstract] [Full Text] [Related]

  • 35. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.
    Srole DN, Ganz T.
    J Cell Physiol; 2021 Jul 01; 236(7):4888-4901. PubMed ID: 33372284
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
    Olivera J, Zhang V, Nemeth E, Ganz T.
    Blood Adv; 2023 Jul 25; 7(14):3339-3349. PubMed ID: 36995275
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Erythroferrone contributes to iron mobilization for embryo erythropoiesis in iron-deficient mouse pregnancies.
    Sangkhae V, Yu V, Coffey R, O'Brien KO, Ganz T, Nemeth E.
    Am J Hematol; 2022 Oct 25; 97(10):1348-1358. PubMed ID: 36071577
    [Abstract] [Full Text] [Related]

  • 40. Characterization of erythroferrone structural domains relevant to its iron-regulatory function.
    Srole DN, Jung G, Waring AJ, Nemeth E, Ganz T.
    J Biol Chem; 2023 Dec 25; 299(12):105374. PubMed ID: 37866631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.